Background/Aim. The cataract surgery in eyes with and
without glaucoma results in the sustained intraocular pressure (IOP) reduction but it is still unknown which glaucomatous patients will achieve clinically significant reduction.
The preoperative IOP and some ocular biometric parameters have been shown as potential predictors of the postoperative IOP reduction. The aim of our prospective intervention study was to evaluate that relationship in medically controlled patients with the pseudoexfoliation glaucoma (PXG)
and in the nonglaucomatous patients. Methods. Thirty-one
PXG patients (31 eyes) and 31 nonglaucomatous patients
(31 eyes), all with clinically significant cataract, were enrolled. The preoperative IOP, anterior chamber depth
(ACD), axial length (AL), lens thickness (LT), lens position
(LP) [LP = ACD + 0.5 LT], relative lens position (RLP)
[RLP = LP / AL] and the pressure-to-depth ratio (PD ratio)
[PD ratio = preoperative IOP/preoperative ACD] were
evaluated as potential predictors of the IOP change in the
6th postoperative month. Results. In the 6th postoperative
month, in the PXG group, the IOP reduction was -3.23 ±
3.41 mmHg (-17.67 ± 16.86%) from the preoperative value
of 16.27 ± 3.08 mmHg and in the control group, the reduction was -2.26 ± 1.71 mmHg (-15.06 ± 10.93%) from the
preoperative value of 14.53 ± 2.04 mmHg. In the PXG
group, the significant predictors of the absolute and the
percentage IOP reduction were the preoperative IOP, AL,
and PD ratio. In the same group, RLP was shown as a significant predictor of absolute change in the IOP in multivariate analysis, and the percentage IOP change in both the
univariate and the multivariate analyses. In the control
group, the preoperative IOP and the PD ratio were the only
significant parameters that could predict absolute change in
the postoperative IOP. Conclusion. The cataract surgery
leads to the IOP reduction both in the PXG and nonglaucomatous eye. Predictors monitored in this study are widely
available and simply calculable parameters that can be potentially used in managing glaucoma.
